Biamonte, Marco, PhD

CEO, Drug Discovery for Tropical Diseases marcoDOTbiamonteATddtdDOTorg

Marco is the founder of Drug Discovery for Tropical Diseases, a non-profit start-up dedicated to finding new treatments for diseases that are associated with poverty. Marco was previously a Senior Scientist at Biogen-Idec (2006-2011) and a Scientist at Conforma Therapeutics (2001-2006) as well as at Serono (1999-2001). Marco was part of the team that delivered the first oral Hsp90 inhibitor (Phase II, oncology), acquired by Biogen Idec for $250 million. Marco delivered two other Hsp90 inhibitors for cancer (Phase I) and immunology (Development), respectively. Marco obtained his Ph.D. from the University of Cambridge, UK, and performed post-doctoral work with Prof. A. Vasella at the Swiss Institute of Technology (ETH-Zürich).
Listen to an interview with Marco